The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 06, 2015

Filed:

Oct. 15, 2013
Applicant:

Tracon Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

Charles Theuer, Carlsbad, CA (US);

Maximiliano Vasquez, Palo Alto, CA (US);

Assignee:

Tracon Pharmaceuticals, Inc., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4045 (2006.01); A61K 31/44 (2006.01); A61K 31/69 (2006.01); A61K 31/704 (2006.01); A61K 47/48 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4045 (2013.01); A61K 31/44 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 39/3955 (2013.01); A61K 47/48561 (2013.01); C07K 16/2896 (2013.01); G01N 33/57492 (2013.01); G01N 33/57496 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.


Find Patent Forward Citations

Loading…